The U.S. Food and Drug Administration has approved GSK's Nucala (mepolizumab) as an add-on maintenance treatment for adult ...

The U.S. Food and Drug Administration has approved Nucala as a supplementary treatment for elderly individuals with severe ...

GSK plc (NYSE:GSK) has strengthened its market outlook following major regulatory milestones. The U.S. FDA’s recent approval ...

The U.S Food and Drug Administration has approved Nucala, British drugmaker GSK's asthma drug, to treat some patients with a ...

Regeneron shares fell nearly 13% before the bell on Friday after its experimental drug for patients with a type of lung ...

The US Food and Drug Administration (FDA) has approved mepolizumab as a maintenance treatment for chronic obstructive ...

Results released Friday show itepekimab succeeded in one Phase 3 trial but failed in a second, sinking shares of both partner ...

Biologics like mepolizumab are providing renewed optimism for those affected by COPD." Approval of Nucala was granted to GSK. More Information ...

GSK has highlighted approval of Nucala in COPD as one of its top 2025 priorities, adding to its established medicines for the disease, including Trelegy (fluticasone furoate, umeclidinium ...

It has previously suggested approval for COPD could come in the US in the first half of next year. Nucala has been approved to treat severe eosinophilic asthma for almost a decade, and in the ...

Despite hiring a commercial chief and sponsoring disease awareness efforts last year, Savara will have to wait a while longer ...